TODAYRead today's current affairs →
YouTubeInstagram
Tathyo
JobsCurrent AffairsInternational RelationsPolityEconomyEducationStore
अ हिंदीSubscribe

The week's essentials, straight to your inbox

Top explainers, current affairs revision and new job alerts. No spam.

Tathyo

Current affairs, international relations, education and govt jobs — explained simply and in depth.

CategoriesCurrent AffairsInternational RelationsPolityEconomyEducationScience & Tech
ExploreSarkari JobsResultsAdmit CardStore
TathyoAboutContactPrivacy PolicyDisclaimerहिंदी संस्करण
© 2026 Tathyo. All rights reserved.RSS
Home/Science & Tech
Science & Tech

India's First Indigenous H5N1 Bird Flu Vaccine for Chickens: ICAR-NIHSAD Vaccine to Be Dedicated to the Nation on 20 November

ICAR-NIHSAD, Bhopal has developed India's first indigenous inactivated vaccine against H5N1 clade 2.3.2.1a for chickens. Shivraj Singh Chouhan is scheduled to dedicate it to the nation on 20 November 2026. Key facts, the current culling policy, the One Health angle and challenges.

Ankit KumarAnkit Kumar · Founder & Editor, Tathyo18 Nov 2026 · 8 min read
In this article1. Why in the news?2. Background3. Key facts/provisions4. Significance5. Challenges6. Way forward7. Facts for Prelims8. Mains practice question9. FAQs10. Sources

Why in the news?

On 18 November 2026, the Ministry of Agriculture and Farmers Welfare announced that Union Minister Shivraj Singh Chouhan will dedicate India's first indigenous vaccine against H5N1 avian influenza (bird flu) for chickens to the nation on 20 November 2026. The vaccine has been developed by the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal, and the dedication is scheduled to take place at the institute's campus in Bhopal.

The announcement comes at a time when fresh outbreaks have been reported. The Federal reported that H5N1 was confirmed in poultry farms in Cuddalore district of Tamil Nadu in November 2026, and an outbreak was reported in Anantapur district of Andhra Pradesh in October 2026.

Background

  • Avian influenza is a viral disease of birds caused by influenza type A viruses. Strains such as H5N1 and H5N8 are highly pathogenic (HPAI). In infected poultry they can kill almost the entire flock, and outbreaks usually lead to mass culling and trade restrictions.
  • India first detected H5N1 in 2006. According to the figures shared with the announcement, the country has recorded more than 500 outbreaks of H5N1 and H5N8 combined since then.
  • Present control policy: The Department of Animal Husbandry and Dairying (DAHD) follows a "detect and cull" approach. In an April 2025 release, DAHD described culling, movement restrictions and disinfection within a 1 km radius of an outbreak site, with farmers compensated for culled birds, destroyed eggs and feed under the Livestock Health and Disease Control Scheme (cost shared 50:50 by the Centre and states).
  • Vaccination so far: ICAR-NIHSAD had earlier developed an inactivated vaccine against low pathogenic avian influenza (H9N2), whose technology was transferred to four companies in December 2022. DAHD later permitted its use. For HPAI, however, DAHD said in April 2025 that no decision had been taken on vaccination, noting that available HPAI vaccines reduce virus shedding but do not give sterile immunity.
  • At a July 2024 DAHD brainstorming session on avian influenza under the One Health approach, experts advised continuing "surveillance and culling with no vaccination" while pushing research on vaccines for both poultry and humans. The same release noted that ICAR-NIHSAD had taken the lead in developing an indigenous HPAI vaccine.

Key facts/provisions

Point Detail
Vaccine Inactivated H5N1 (HPAI) vaccine for chickens
Target strain H5N1 clade 2.3.2.1a
Developer ICAR-NIHSAD, Bhopal (an institute of the Indian Council of Agricultural Research)
Announced 18 November 2026, Ministry of Agriculture and Farmers Welfare
Dedication to the nation 20 November 2026 (scheduled), ICAR-NIHSAD, Bhopal
Dedicated by Union Agriculture Minister Shivraj Singh Chouhan
Gap it fills No specific commercial vaccine was available for clade 2.3.2.1a

Other figures shared with the announcement (as reported by Rural Voice and ANI):

  • Clade 2.3.2.1a is responsible for most chicken outbreaks in India and has recently infected other animal species, including mammals; three human infections have been linked to it in recent years.
  • A major outbreak could cut India's GDP growth by up to 1.5%, and more than 20% of the poultry population could be at risk if the disease spread unchecked.
  • The 2006 outbreak caused estimated direct and indirect losses of Rs 2,200-3,000 crore; an outbreak in Manipur caused losses equal to about 0.5% of the state's GDP.
  • Citing WHO, the release noted 1,003 human H5N1 cases and 479 deaths across 25 countries since 2003.

Details such as the dose schedule, regulatory licensing, commercial manufacturing partners and the rules for its field use have not been officially detailed yet. Official information on these points is not yet available; readers should check the Ministry's and ICAR's websites for updates.

Significance

  1. Self-reliance in animal health: A home-grown vaccine matched to the strain actually circulating in Indian poultry reduces dependence on vaccines developed abroad for other clades.
  2. A new tool for poultry farmers: Repeated culling destroys flocks and livelihoods. A vaccine could, if approved for use, lower losses for poultry farms that are now forced to cull entire flocks.
  3. Economic protection: Poultry is a major source of affordable protein and rural income. The loss estimates linked to past outbreaks show what is at stake for the sector and the wider economy.
  4. One Health: H5N1 moves between birds, mammals and, rarely, humans. Reducing virus load in poultry can lower the chances of spillover, which is the central idea of the One Health approach that DAHD has adopted for avian influenza.
  5. Research capacity: ICAR-NIHSAD, as its name suggests, is a high-security animal disease institute. The new vaccine builds on its earlier H9N2 vaccine and shows the value of such specialised public research.

Challenges

  • Policy shift needed: India's official approach has been surveillance and culling without HPAI vaccination. How and where this vaccine will be used is a policy decision that DAHD has not yet announced.
  • No sterile immunity: As DAHD itself noted, HPAI vaccines generally reduce shedding rather than fully stop infection. Vaccinated flocks could carry the virus silently unless surveillance is strong.
  • Telling infected from vaccinated birds: Export markets and disease-free status depend on being able to show that birds are not infected. This usually requires special testing strategies.
  • Virus evolution: Influenza viruses change constantly; a clade-specific vaccine will need regular monitoring and updating.
  • Backyard poultry: Small and backyard flocks are hard to reach for vaccination, biosecurity and movement control.
  • Scale and cost: Manufacturing, cold chain and delivery to millions of birds will need industry partners and funding.

Way forward

  • Issue clear national guidelines on whether vaccination will be targeted (for example, high-risk zones or breeder flocks) or wider, alongside existing culling rules.
  • Pair vaccination with stronger surveillance, farm registration and biosecurity, which DAHD has already called for.
  • Transfer the technology to manufacturers, as was done for the H9N2 vaccine, to make doses available at scale.
  • Strengthen One Health coordination between animal husbandry, health and environment agencies, including surveillance of migratory birds and wild animals.
  • Keep tracking circulating strains so that the vaccine stays matched to the virus.

Facts for Prelims

  • Vaccine: India's first indigenous inactivated H5N1 vaccine for chickens, against clade 2.3.2.1a.
  • Developer: ICAR-NIHSAD, Bhopal (Madhya Pradesh).
  • Dedication: 20 November 2026 (scheduled), by Union Agriculture Minister Shivraj Singh Chouhan.
  • First H5N1 detection in India: 2006.
  • H9N2 (LPAI) vaccine: Also developed by ICAR-NIHSAD; technology transferred in December 2022.
  • Control policy: Detect and cull, with movement restriction and disinfection within 1 km of an outbreak; compensation shared 50:50 by the Centre and states under the Livestock Health and Disease Control Scheme.

Mains practice question

"India has relied on culling to control highly pathogenic avian influenza." In the light of the indigenous H5N1 vaccine for poultry, discuss the benefits and risks of adding vaccination to India's bird flu control strategy within a One Health framework. (250 words)

FAQs

Who developed India's first indigenous H5N1 vaccine for chickens?

It was developed by the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal.

When will the vaccine be dedicated to the nation?

Union Minister Shivraj Singh Chouhan is scheduled to dedicate it to the nation on 20 November 2026 at ICAR-NIHSAD, Bhopal.

Which strain does the vaccine target?

It is an inactivated vaccine against H5N1 clade 2.3.2.1a, the clade linked to most chicken outbreaks in India.

Does this mean India will stop culling birds?

Not as of now. DAHD's policy is detect and cull, and no official decision on HPAI vaccination policy has been announced. The vaccine is expected to complement surveillance, biosecurity and culling.

Sources

  • PIB (DAHD): Government and poultry industry collaborate to prevent bird flu outbreaks, 5 April 2025
  • PIB (DAHD): High-level brainstorming session on avian influenza under One Health approach, 17 July 2024
  • PIB (Agriculture): Transfer of technology of ICAR-NIHSAD's H9N2 vaccine for chickens, 27 December 2022
  • The Federal: India develops its own H5N1 vaccine amid fresh bird flu outbreaks, 18 November 2026
  • Rural Voice: India to get its first indigenous H5N1 bird flu vaccine for chickens on November 20
  • Asianet Newsable (ANI): India unveils first indigenous H5N1 bird flu vaccine for poultry use
#H5N1#bird flu#ICAR-NIHSAD#avian influenza#One Health#poultry vaccine
Ankit Kumar
AuthorAnkit KumarFounder & Editor, Tathyo

Ankit Kumar is the founder and editor of Tathyo. He works with BPSC and UPSC aspirants at GS Hub, Patna. At Tathyo, he oversees fact-checking so every article is exam-relevant and based on official sources.

Read also

विज्ञान
Science & Tech

ICMR's AMR Surveillance Report 2025: Why Common Antibiotics Are Losing Their Power

The annual report of ICMR's Antimicrobial Resistance Surveillance and Research Network for 2025, reported in November 2026, shows high resistance among E. coli, Klebsiella and Acinetobacter, and for the first time includes district hospitals.

Ankit Kumar · 8 min · 19 Nov 2026
विज्ञान
Science & Tech

Voyager 1 Reaches One Light-Day from Earth: A Milestone 49 Years in the Making

On 18 November 2026, NASA's Voyager 1 became the first human-made object to reach one light-day from Earth — about 25.9 billion km — so a radio command now takes a full 24 hours to reach it.

Ankit Kumar · 7 min · 19 Nov 2026
विज्ञान
Science & Tech

India's Space Sector Reforms: Opening the Skies to Private Firms and the Success of Vikram-1

From the 2020 reforms to IN-SPACe, the Space Policy 2023 and liberal FDI rules, India's space sector is open to private players. In July 2026 Skyroot's Vikram-1 made the country's first private orbital launch.

Ankit Kumar · 7 min · 17 Nov 2026